Welcome to the e-CCO Library!

P518: Remission induction in corticosteroid naïve children and adolescents with ulcerative colitis by adsorptive leucocytapheresis as monotherapy or in combination with low dose prednisolone after failure of first-line medications
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Tanaka T.*1, Goishi H.1, Kajihara T.1, Akagi M.1, Saniabadi A.2, Miura T.1

Created: Wednesday, 20 February 2019, 10:36 AM
P518: Safety of upadacitinib in ulcerative colitis: Long-term data from the phase 3 open-label extension study (U-ACTIVATE)
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Panaccione, R.(1)*;Lichtenstein, G.(2);Nakase, H.(3);Armuzzi, A.(4);Kucharzik, T.(5);Levy, G.(6);Palac, H.(6);Kujawski, M.(6);Klaff, J.(6);Cheon, J.H.(7);
Created: Friday, 14 July 2023, 11:05 AM
P518: Vedolizumab trough concentrations are associated with endoscopic response in patients with inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

C.-Y. Chao1,2*, S. Restellini1,3, C. Lemieux1, P. Germain1, A. Bitton1, P.L. Lakatos1,4, G. Wild1, E. Seidman1, T. Bessissow1, W. Afif1

Created: Thursday, 21 February 2019, 9:14 AM
P519 Higher anti-TNF α trough levels are not associated with increased radiological response in perianal fistulising Crohn’s disease: A multicentre study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

T. LEE1, L. Gilbert2, A. Srinivasan3, A. Lee4, D. van Langenberg3, C. Martin5, N. Ding1, M. Sparrow2

Created: Thursday, 30 January 2020, 10:12 AM
P519: Analysis of the effectiveness and safety of switching from originator to biosimilar adalimumab in patients with Inflammatory Bowel Disease
Year: 2022
Source: ECCO'22
Authors: Casanova, M.J.(1);Chaparro, M.(1);Nantes, Ó.(2);Varela, P.(3);Vela-González, M.(4);Montserrat, R.(5);Sierra, O.G.(6);Riestra, S.(7);Barreiro-de Acosta, M.(8);Martín-Rodríguez, M.M.(9);Gargallo-Puyuelo, C.J.(10);Reygosa, C.(11);Muñoz, R.(12);García de la Filia-Molina, I.(13);Núñez-Ortiz, A.(14);Kolle, L.(15);Calafat, M.(16);Huguet, J.M.(17);Iglesias-Flores, E.(18);Martínez-Pérez, T.J.(19);Bosch, O.(20);Duque-Alcorta, J.M.(21);Frago-Larramona, S.(22);Sánchez-Azofra, M.(23);Van Domselaar, M.(24);González-Cosano, V.M.(25);Bujanda, L.(26);Rubio, S.(2);Mancebo, A.(3);Castro, B.(5);García-López, S.(6);de Francisco, R.(7);Nieto, L.(8);Laredo, V.(10);Gutiérrez, A.(12);Mesonero, F.(13);Leo-Carnerero, E.(14);Cañete, F.(16);Ruiz, L.(17);Gisbert, J.P.(1);
Created: Friday, 11 February 2022, 3:56 PM
P519: Anti-tumour necrosis-alpha therapy during pregnancy in patients with inflammatory bowel disease: safety in women and children
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Bernardes C., Loureiro R., Carvalho D., Borges V., Russo P., Saiote J., Ramos J.

Created: Wednesday, 20 February 2019, 10:36 AM
P519: Impact of skin examination prior to initiation of biological treatment in patients with Inflammatory Bowel Disease: preliminary data
Year: 2021
Source: ECCO'21 Virtual
Authors: Hartl, C.(1);Novacek, G.(2);Reinisch, S.(2);Saciri, A.(1);Reinisch, W.(2);Primas, C.(2);Maier, H.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P519: Mirikizumab pharmacokinetics and exposure-response relationships in patients with moderately to severely active ulcerative colitis: results from randomised phase 2 and phase 3 induction and maintenance trials
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Friedrich, S.(1);Chua, L.(1);Zhang , X.C.(1);Clemow, S.(1)*;
Created: Friday, 14 July 2023, 11:05 AM
P519: Post-surgical recurrence predictors in the years 2000. Results of a retrospective single-centre long-term follow-up series and impact of imaging findings on outcomes
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Mendolaro*1, M. Daperno1, C. Randazzo2, A. Lavagna1, M. Mineccia3, M. Cosimato1, F. Bertolino4, C. Rigazio1, E. Ercole1, A. Ferrero3, R. Rocca1

Created: Friday, 22 February 2019, 9:41 AM
P519: Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: Multicentre study at 12 months results
Year: 2018
Source: ECCO '18 Vienna
Authors:

M.F. Guerra Veloz1*, M. Belvis Jimenez1, J.M. Vázquez Morón2, H. Pallarés Manrique2, T. Valdes Delgado1, L. Castro Laria1, B. Maldonado Pérez1, R. Perea Amarillo1, V. Merino3, A. Caunedo Álvarez1, F. Argüelles-Arias1

Created: Thursday, 21 February 2019, 9:14 AM
P520 Association between ustekinumab trough levels and biomarkers in patients with Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M.I. Nicolás de Prado1, C. Iniesta Navalón2, R. Gomez Espin1, M. Gil Candel2, L. Serrano Díaz1, L. Rentero Redondo2, J.J. Martinez Crespo1

Created: Thursday, 30 January 2020, 10:12 AM
P520: Endoscopic evaluation and factors affecting the endoscopic efficacy during granulomonocytapheresis in moderately-to-severely active ulcerative colitis: a multi-centre retrospective study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

T. Yamamoto1, T. Iida2, K. Ikeya2, M. Kato2, A. Matsuura2, S. Tamura3, R. Takano3, S. Tani4, S. Osawa4, K. Sugimoto3, T. Shimoyama*1, H. Hanai2

Created: Friday, 22 February 2019, 9:41 AM
P520: Gastrointestinal ultrasonography in pregnant patients with IBD is useful in the identification of active intestinal inflammation
Year: 2018
Source: ECCO '18 Vienna
Authors:

E. Flanagan1, E. Wright1, J. Begun2,3, R. Bryant4,5, D. Sathananthan4, S. Bell1*

Created: Thursday, 21 February 2019, 9:14 AM
P520: Perspective and self-efficacy of adolescents with inflammatory bowel disease post transition to adult care
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Yadav A., Forry M., O'Toole A., Patchett S.

Created: Wednesday, 20 February 2019, 10:36 AM
P520: Thromboembolic and major adverse cardiovascular events among patients in the filgotinib clinical trial programme
Year: 2023
Source: ECCO’23 Copenhagen
Authors: van der Woude, J.(1)*;Schreiber , S.(2);Peyrin-Biroulet , L.(3);Szekanecz, Z.(4);Choy, E.H.(5);Stiers, P.J.(6);Van Hoek, P.(7);Van Beneden, K.(8);de Haas, A.(9);Rudolph , C.(10);ten Cate, H.(11);
Created: Friday, 14 July 2023, 11:05 AM
P520: Very early intestinal ultrasound predicts intravenous corticosteroid failure in hospitalized severe ulcerative colitis patients
Year: 2022
Source: ECCO'22
Authors: Fremberg Ilvemark, J.(1);Wilkens, R.(2);Thielsen, P.(1);Kirch Dige, A.(3);Boysen, T.(2);Brynskov, J.(1);Tveiten Bjerrum, J.(1);Seidelin, J.(1);
Created: Friday, 11 February 2022, 3:56 PM
P520: ‘Eetscore’ in patients with Inflammatory Bowel Disease: an online tool to assess diet quality and provide personalised dietary advice
Year: 2021
Source: ECCO'21 Virtual
Authors: Lamers, C.R.(1,2);van Erp, L.W.(3);Slotegraaf, A.I.(2);Groenen, M.J.M.(3);de Roos, N.M.(2);Wahab, P.J.(3);Witteman, B.J.M.(1,2);
Created: Wednesday, 2 June 2021, 4:12 PM
P521 Infection of the anal canal by human papillomavirus in Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

V. Guzela1, C. Sobrado Júnior1, S. Nadal2, C.R. Nadal2, L.L. Villa3, A.P. Gonçalves1, L.R. Boarini1, S.C. Nahas1, I. Cecconello1

Created: Thursday, 30 January 2020, 10:12 AM
P521: A prospective cohort study to assess the relevance of Vedolizumab drug level monitoring in IBD patients
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Schulze H.*1, Esters P.1, Hartmann F.1, Stein J.2, Christ C.3, Zorn M.3, Dignass A.1

Created: Wednesday, 20 February 2019, 10:36 AM
P521: Correlation between physician disease assessment in Ulcerative Colitis and burden of disease: ICONIC 2-year data of 120 patients in Turkey
Year: 2021
Source: ECCO'21 Virtual
Authors: Sezgin, O.(1);Atug, O.(2);Gonen, C.(3);Can, G.(4);Duman, A.E.(5);Erzin, Y.Z.(6);Yurci, M.A.(7);Alkim, C.(8);Unal Ozcelik, N.G.(9);Yildirim, B.(10);Kayacetin, E.(11);Beyazit, Y.(12);Tayfur Yurekli, O.(11);Kiyici, M.(13);
Created: Wednesday, 2 June 2021, 4:12 PM